Table 1.
Characteristics of the participants evaluated at 1 year
| Participation at 1 year |
P value | ||
|---|---|---|---|
| No N = 120 |
Yes N = 366 |
||
| Age (years), mean (SD) | 68.1 (6.95) | 67.8 (7.27) | 0.736 |
| Education (years), median (P25-P75) | 4 (4-8) | 5 (4-10) | 0.013 |
| MoCA, mean (SD) | 20.6 (4.13) | 22.4 (3.69) | <0.001 |
| Cancer stage, n (%) | 0.001 | ||
| I | 14 (11.7) | 20 (5.5) | |
| II | 63 (52.5) | 150 (41.0) | |
| II/III | 3 (2.5) | 3 (0.8) | |
| III | 28 (23.3) | 116 (31.7) | |
| IV | 12 (10.0) | 77 (21.0) | |
| Treatments, n (%) | 0.006 | ||
| Active surveillance | 8 (6.7) | 18 (4.9) | |
| Brachytherapy | 37 (31.1) | 52 (14.2) | |
| RT | 13 (10.9) | 38 (10.4) | |
| RP | 22 (18.5) | 59 (16.1) | |
| RT + ADT (6 months) | 15 (12.6) | 35 (9.6) | |
| RT + ADT (24 months)a | 16 (13.8) | 90 (24.6) | |
| ADT (incident disease) | 4 (3.4) | 22 (6.0) | |
| ADT + chemotherapy | 1 (0.8) | 12 (3.3) | |
| ADT (recurrent disease) | 6 (5.0) | 25 (6.8) | |
| RT + palliative ADT | 0 | 1 (0.3) | |
| RP + RT | 2 (1.7) | 13 (3.6) | |
| RP + ADT | 0 | 1 (0.3) | |
ADT, androgen-deprivation therapy; MoCA, Montreal Cognitive Assessment; P25, percentile 25; P75, percentile 75; RP, radical prostatectomy; RT, radiotherapy; SD, standard deviation.
a
Participants were proposed for 24 months of ADT and were still on ADT at the 1-year evaluation.